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ABSTRACT  
 
Cancer is defined as a group of more than 100 diseases responsible for 
uncontrolled cellular growth, local tissue invasion and distant metastases. In 2012, the 
World Health Organization expected a rise by about 70% of the number of new cases of 
cancer in the next two decades.  
With the exponential development of cancer and the low survival ratio for 
leukaemia and lymphoma, it is urgent to develop new drugs able to fight cancer cells 
and improve anticancer treatments. The study of bis-indolyl methane (BIM) compounds 
may constitute a valuable contribution to tackle this problem. 
BIM, also known as 3,3-di-indolylmethane, is a natural metabolite of indole-3-
carbinol that occurs in Brassica genus plants (cruciferous plants); and with described 
biological activities such as antibacterial, antifungal, analgesic, anti-inflammatory, 
anthelmintic, cardiovascular and anticancer.  
The main objectives of this work were to study the cytotoxic activity of BIMs with 
oxime and hydrazone derivatives, to relate their chemical structure with the cytotoxic 
activity and to compare BIMs with actual therapeutics. The cytotoxic assays were done 
in THP-1 (leukaemia), EL-4 and U937 (lymphoma) and S17 (bone marrow) cell lines; and 
revealed that CG-141 was the most active compound towards EL-4, THP-1 and U937 
while AL-522B was the most selective compound towards S17. When compared with 
hydrazone derivatives, oxime derivatives had a stronger biological activity in the studied 
cell lines.  
Relating the studied compounds with the compound 9a, it was possible to 
conclude that 9a continues to be the most biological active compound towards EL-4, 
THP-1 and U937 and the most selective towards S17.  
None of the studied compounds presented significant hemolytic activity in a 
hemolytic assay, which corroborated the theory of a nuclear action mechanism. BIMs 
and vinca alkaloids have the same pharmacophores, which suggests that they might 
have a similar mechanism of action. 
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RESUMO ALARGADO 
 
O cancro é definido com um grupo de mais de 100 patologias responsáveis pelo 
crescimento celular descontrolado, invasão de tecidos e metástases. Classificado de 
acordo com o tipo de células que o constituem, este pode ser designado por carcinoma, 
sarcoma, leucemia, linfoma, mieloma múltiplo, melanoma ou outros tipos de cancro.  
Sendo a segunda causa de morte na Europa e nos Estados Unidos da América, a 
Organização Mundial de Saúde esperava, em 2012, um aumento de cerca de 70% de 
novos casos de cancro nas duas décadas seguintes. 
Com mecanismos bastante complexos, a carcinogénese é classificada em três 
fases, sendo elas: iniciação – exposição das células normais a substâncias carcinogénicas 
ou a alterações genéticas; promoção – quando as células sujeitas a agentes cancerígenos 
e fatores de crescimento ambientais se tornam cancerígenas; e progressão – quando há 
o aumento de proliferação celular, resultando num tumor ou desenvolvimento de 
metástases. Além destas três fases, existem também um total de dez características que 
são adquiridas durante o desenvolvimento de um tumor, compreendendo capacidades 
biológicas fundamentais das células cancerígenas: i) sinal proliferativo permanente; ii) 
fuga aos supressores de crescimento; iii) resistência à morte celular; iv) capacidade de 
imortalidade replicativa; v) indução da angiogénese; vi) ativação da invasão e 
metastização das células cancerígenas; vii) reprogramação da energia celular; viii) 
evasão às defesas imunológicas; ix) instabilidade do genoma; e x) inflamação promotora 
de tumores.  
Dentro das doenças oncológicas incluem-se as leucemias e os linfomas. Existem 
quatro tipos principais de leucemias: leucemia mieloide aguda, leucemia mieloide 
crónica, leucemia linfoblástica aguda e leucemia linfocítica crónica; e dois grandes 
grupos de linfomas, Hodgkin e Não-Hodgkin, que incluem um total de mais de 50 
subtipos.  
Existem diferentes modalidades de combate ao cancro entre as quais se inclui a 
quimioterapia. Esta utiliza fármacos classificados como: 
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i) Agentes alquilantes que podem atuar por DNA cross-link (ex.: mecloretamina, 
carmustina, busulfano), por metilação do DNA (ex.: procarbazina) e por ligação cruzada 
intra e inter cadeias de DNA (ex.: cisplatina, carboplatina e oxaliplatina);  
ii) Antimetabolitos que atuam por competição, inibindo a biossíntese de 
nucleótidos (ex.: antifolatos como o metotrexato, fluoropirimidinas como o 5-
fluoruracilo, análogos da desoxicitidina como a citarabina e análogos das purinas como 
a 6-mercaptopurina);  
iii) Produtos naturais: alcaloides da vinca (ex.: vimblastina, vincristina e 
vinorelbina) que inibem a mitose por polimerização da tubulina; taxanos (ex.: paclitaxel) 
que também inibem a mitose; epipodofilotoxinas (ex.: etoposido que inibe a 
topoisomerase II); e camptotecinas (ex.: topotecano e irinotecano) que inibem a 
topoisomerase I; 
iv) Antibióticos, incluindo antraciclinas (ex.: doxorrubicina) que inibem a 
topoisomerase II, intercalam o DNA e libertam radicais livres de oxigénio, mitomicina e 
bleomicina que atuam por um mecanismo de alquilação e de libertação de radicais, 
respetivamente;  
v) Fármacos mistos que incluem o imatinib, o dasatinib, o nilotinib, inibidores dos 
recetores dos fatores de crescimento e asparaginase.  
Com o desenvolvimento exponencial do cancro e a baixa taxa de sobrevivência a 
leucemias e linfomas, há uma grande necessidade de desenvolvimento de novos 
fármacos capazes de combater células cancerígenas e melhorar os tratamentos 
oncológicos, uma vez que estes apresentam bastantes efeitos adversos (náuseas, 
vómitos, diarreia, fadiga, mielossupressão, neutropenia, trombocitopenia, 
hepatotoxicidade, alopecia, mucosite, entre outros). O estudo de bis(indolil)metanos 
(BIMs) poderá constituir uma vantagem face a este grande grupo de doenças, em 
especial, leucemia e linfomas.   
BIM, também conhecido como 3,3-diindol metano, é um metabolito natural do 
indole-3-carbinol, que está presente em plantas do género Brassica (plantas crucíferas 
como brócolos, couves de bruxelas, couve-flor, couve e repolho) e tem descritas 
atividades biológicas como atividade antibacteriana, antifúngica, analgésica, anti-
inflamatória, anti-helmíntica, cardiovascular e anticancerígena.  
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Durante o processo de desenvolvimento de um fármaco existem diferentes 
etapas envolvidas: descoberta, design e desenvolvimento. A etapa de design de um 
fármaco consiste na identificação de relação estrutura-atividade deste, assim como do 
seu farmacóforo, de modo a melhorar as propriedades farmacodinâmicas e 
farmacocinéticas.  Contudo, devido à utilização de recursos limitados e às limitações 
impostas à experimentação animal ao longo dos últimos anos, esta componente do 
desenvolvimento tem-se tornado cara e longa. Assim, e como forma de colmatar estas 
dificuldades, surgiram os modelos computacionais de relação estrutura-atividade e 
estudos in silico.  
Os principais objetivos deste trabalho consistiram no estudo da atividade 
citotóxica dos BIMs com derivações de oximas e hidrazonas, na relação da estrutura 
química com a respetiva atividade citotóxica e na comparação dos BIMs com os 
fármacos atualmente usadas em terapêutica.  
Desta forma, começou por se determinar a atividade citotóxica dos compostos 
em estudo (derivados de oximas: CG-99-1, CG-109, CG-141 e CG-142; derivados de 
hidrazonas: AL-516, AL-522B, CG-92, CG-105, CG-147, CG-151 e CG-153) e do composto 
etoposido nas linhas celulares de EL-4 (linfoblastos de murino), THP-1 (leucemia aguda 
monocítica humana), U937 (linfoblastos de pulmão humanos) e S17 (estroma de medula 
óssea de murino), mediante ensaio colorimétrico com MTT, seguindo-se o cálculo da 
respetiva seletividade. Foi também determinada a atividade hemolítica dos compostos 
em estudo. Os resultados revelaram que o composto CG-141 foi o que apresentou 
melhor atividade biológica: EL-4 (IC50=3,01-3,47 µM), THP-1 (IC50=5,79-6,94 µM) e U937 
(IC50=9,79-10,3 µM). Já o composto AL-522B apresentou melhores valores de 
seletividade face à linha celular S17: 3,10 para EL-4, 2,49 para THP-1 e 2,55 para U937. 
Quando comparados com os derivados de hidrazonas, os BIM derivados de oximas 
revelaram maior atividade biológica nas linhas celulares estudadas.  
Relativamente ao composto 9a, analisado num estudo prévio, este continua a 
apresentar melhor atividade biológica e seletividade nas linhas celulares estudadas, 
destacando assim a importância do hidrogénio na posição R2 do BIM. Quando compara 
a atividade citotóxica do composto 9a com o etoposido, verificaram-se valores de IC50 
semelhantes, traduzindo-se numa atividade citotóxica bastante similar entre ambos. 
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Nenhum dos compostos estudados apresentou atividade hemolítica significativa, 
corroborando desta forma a teoria de um mecanismo de ação a nível nuclear.  
Ao comparar a estrutura dos BIMs com os fármacos atualmente utilizados em 
terapêutica, foi possível concluir que os BIMs e os alcaloides da vinca apresentam o 
mesmo farmacóforo – dois índoles -, o que pode sugerir um mecanismo de ação 
semelhante.  
Em conclusão, novas estratégias de abordagem química e ensaios biológicos 
devem ser feitos de modo a complementar os dados obtidos e a melhorar moléculas 
com potencial de utilização citotóxica. A utilização de substituintes alquil e aril 
juntamente com oximas e hidrazonas sugerem a criação de compostos promissores no 
tratamento de células tumorais não aderentes. Grupos heteroarilo, fosforilo, carbonilo 
e carboxilo poderão ser abordagens interessantes na medida em que também fazem 
parte da estrutura de fármacos atualmente utilizados. Relativamente aos ensaios 
biológicos, são necessárias melhorias nos ensaios realizados assim como a realização de 
ensaios complementares, com o objetivo de permitir esclarecer o mecanismo de ação 
dos compostos em causa.  
 
 
Palavras-chave:  bis(indolil)metano, atividade citotóxica, derivados de oxima e 
hidrazona, cancro, leucemia, linfoma.  
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I. INTRODUCTION  
 
1.1 Cancer  
 
The oldest evidences suggesting cancer date back to ancient Egypt being referred 
in ancient manuscripts from about 1600 BC. However, the word cancer comes from the 
Greek word karkinos and was firstly used by Hippocrates, a physician who lived between 
460-370 BC, to described carcinoma tumours (1).  
 
Cancer is defined as a group of more than 100 diseases responsible for 
uncontrolled cellular growth, local tissue invasion and distant metastases. If cancer cells 
remain encapsulated or localized we are towards a benign cancer, while cells that invade 
and destroy surrounding tissues characterize malign cancers (2). 
According to the type of cells that form a cancer, it has different classifications:  
- Carcinoma:  is the most common type of cancer and is formed by epithelial cells. 
Carcinomas can be classified in (3):  
- Adenocarcinoma: cancer from epithelial cells that produce fluids 
or mucus (e.g.: breast, colon and prostate cancer) (3).  
- Basal cell carcinoma: cancer that begins in the lower or basal 
layer of the epidermis (e.g.: skin cancer) (3).  
- Squamous cell carcinoma: cancer in squamous cells (e.g.: 
stomach, intestines, lungs, bladder and kidney cancer) (3).  
- Transitional cell carcinoma: cancer in transitional epithelium or 
urothelium (e.g.: some bladder, ureters and kidney cancer) (3).  
- Sarcoma: cancer formed in bone (osteosarcoma) and soft tissues as muscle, fat, 
blood and/or lymph vessels and fibrous tissue (tendons and ligaments) (3).  
- Leukaemia: not-solid tumour that begins in blood-forming tissue of the bone 
marrow (3). This type of carcinoma will be explored in Section 1.1.2.  
- Lymphoma: cancer that begins in lymphocytes (T or B cells) (3). This type of 
carcinoma will be explored in Section 1.1.2.  
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 - Multiple Myeloma:  cancer formed in plasma cells causing myeloma cells, which 
forms tumours in bones (3).  
 - Melanoma: formed when melanocytes are affected causing, mostly, skin cancer 
(3).  
 - Other types of tumours: brain and spinal cord tumours, germs cell tumours, 
neuroendocrine tumours and carcinoid tumours (3).  
  
 The risk factors that are in the origin of cancer can be different, depending on 
the type of cancer. The use of tobacco is the riskiest factor, followed by obesity and 
pathogens (Fig. I-1) (5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I-1. Cancer risk factors that increase individual risk for developing cancer (Adapted from (5)). 
Despite not all risk cancer factors have the same impact on cancer, some of them are recognized as higher risk: 
tobacco use, obesity, infections by some pathogens, lack of physical activity and wrong diet habits are among the 
most common cancer causes.  
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According to GLOBOCAN 2012, 14.1 million new cases of cancer and 8.2 million 
deaths were reported in 2012 worldwide and the World Health Organization (WHO) 
expected, in 2012, a rise by about 70% of the number of new cases of cancer in the next 
two decades (6,7). Actually, cancer is the second cause of death in Europe and in USA, 
after cardiovascular diseases, with lung, breast, colorectal, prostate, stomach and liver 
cancer as the most common in the World (Fig. I-1) (5,8,9). 
 
 
1.1.1 Carcinogenesis mechanisms  
 
The cell cycle is a complex biological process, which is controlled by a series of 
signalling pathways in order to regulate cell grow, DNA replication and division. To 
ensure minimum faults in this process, it includes mechanisms to avoid cellular errors 
(correction mechanisms or suicide mechanism – apoptosis), in order to prevent 
uncontrolled cell proliferation (10). When cells are submitted to modifications in genetic 
programmes (influencing cell proliferation and lifespan) and the relationship with 
neighbouring cells and the capacity to escape the immune system are affected, cells 
change their behaviour and their metabolism, turning into cancer cells. Cancer cells are 
 
Figure I-2.  Estimated number of cancer incidence and mortality in the World (6). 
Lung, Breast, Colorectal, Prostate, Stomach and Liver Cancer are the most common. 
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able to proliferate at a faster rate and invade distant tissues to form metastases, 
perturbing physiological functions (11).   
Basing on the capacity of normal cells to turn into cancer cells, carcinogenesis is 
classified in three phases: initiation, promotion and progression. The initiation phase is 
characterized by the exposition of normal cells to carcinogenic substances (e.g.: 
tobacco) or to genetic changes which are not repaired by the organism, resulting in 
irreversible cellular mutations. When cells reach the promotion phase, they are 
subjected to carcinogens and/or environmental growth factors, being prone to become 
cancerous (conversion or transformation). In the last phase, progression, there is an 
increase of cell proliferation, which results in tumour invasion into local tissues and 
development of metastasis (2).  
In the initiation phase, the genes affected by genetic changes can be classified 
into three types: proto-oncogenes, tumour suppressor genes and DNA repair genes 
(table I-1 presents examples of these genes and the genetic alteration that they can be 
subjected). Proto-oncogenes (or oncogenes) result from normal genes that were 
altered, being more active than normal (there is a gain of function). Thus, oncogenes 
allow faster cell growth and cell proliferation. Like oncogenes, tumour suppressor genes 
also control cellular growth and division, being responsible for the inhibition of cell 
proliferation. When mutated, these genes lose this function, which results in 
uncontrolled cell division. DNA repair genes work as DNA repairers, correcting mutations 
(3).   
Table  I-1. Example of oncogenes and tumour suppressor genes, as well as the kind of genetic alteration that they can be subjected 
(adapted from (12)). 
 Protein Genetic Alterations 
Evading 
Apoptosis 
Self-
Sufficiency 
in Growth 
Status 
Insensitivity 
to Anti-
Growth 
Signals 
Tissue 
Invasion & 
Metastasis 
Sustained 
Angiogenesis 
Akt Signalling Pathway 
 Akt  
Point mutation, 
amplification, increased 
expression 
     
 Bax Point mutation      
 PI3k Point mutation      
 Bcl2 Translocation      
 PTEN Point mutation, deletion      
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Besides the classification in three phases, there are six hallmarks of cancer, which 
are acquired during tumour development and comprise six biological capabilities 
fundamentals to cancerous cells (Fig. I-3): i) sustaining proliferative signalling; ii) evading 
growth suppressors; iii) resisting cell death; iv) enabling replicative immortality; v) 
inducing angiogenesis; and vi) activating invasion and metastasis (13,14).   
Cell Cycle Control: G1/S Checkpoint 
 Abl Translocation      
 p57 Point mutation      
 Rb Point mutation      
Cell Cycle Control: G2/M DNA Damage Checkpoint 
 ATM/ATR Point mutation      
 BRCA1 Point mutation      
 p53 Point mutation, deletion      
Death Receptor Signaling Pathway 
 Fas Point mutation      
Notch Signaling Pathway 
 Notch Translocation      
Ras 
 Ras Point mutation      
 Integrin Deletion      
TGF-β Signalling Pathway 
 Myc 
Point mutation, 
amplification 
     
 TGFβR Point mutation      
Wnt/β-Catenin Signalling 
 β-catenin Point mutation      
 Wnt1 Increased expression      
 APC Point mutation      
 α-catenin Point mutation      
 E-cadherin Point mutation      
 Wnt5A Point mutation      
Other/Transcription Factors 
 BCL6 
Translocation, point 
mutation 
     
        
 Oncogenes       Tumour Suppressor     Protein Function 
        
Table  I-1 (Continuation). Example of oncogenes and tumour suppressor genes, as well as the kind of genetic alteration that they can be 
subjected (adapted from (12)). 
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Figure I-3. The six hallmarks of cancer (13,14)  
The six hallmarks of cancer represent the six basic mechanisms that a cell has to acquire to become cancerous.  
 
Recent studies described two additional hallmarks (Fig. I-4): vii) deregulating 
cellular energetics and viii) avoiding immune destruction; and two enabling 
characteristics: ix) genome instability and mutation and x) tumour-promoting 
inflammation (13).    
 
 
Figure I-4. Additional hallmarks of cancer. (13) 
Emerging hallmarks include the capacity to modify or reprogram cellular mechanism, supporting neoplastic 
proliferation and evade immunological destruction (T and B lymphocytes, macrophages and natural killer cells). 
Enabling characteristics refer to genome instability and consequently cells mutability as well as inflammation by 
innate immune cells.   
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1.1.1.1 Sustaining Proliferation Signalling  
 
 While normal cells are able to control all the proliferative signals, namely 
production and release of growth-promoting signals, in cancer cells this regulation is 
compromised (13).  
 Due to this non-regulation, cancer cells have developed some capabilities to 
sustain proliferative signalling:  
- Increased growth factor production (13);  
- Stimulated normal cells in the microenvironment to provide cancer cells with 
growth factors (13);  
- Increased number of receptors on the cancer cell surface (13);  
- Structurally altered receptors to facilitate cancer cell Signalling; (13) 
- Activated proteins in the downstream signalling pathway (13);  
- Disrupted negative feedback mechanisms that attenuate proliferative 
signalling  (e.g.: Ras oncoprotein which is modify by oncogenic mutations 
affecting ras gene and, consequently, Ras GTPase activity (Fig. I-5)). PTEN 
phosphatase counteracts PI3-kinase and can also be mutated; the loss of 
function by mutations in PTEN amplifies PI3K signalling and promotes 
tumorigenesis. Another example is mTOR kinase, which functions as 
coordinator of cell growth and metabolism; mTOR activation results in the 
inhibition of PI3-K signalling. When mTOR is pharmacologically inhibited in 
cancer cells, PI3-K activity increases and cellular proliferation is enhanced 
(13).  
 
 
 
 
 
 
 
Figure I-5. Sustaining proliferative signalling (15). 
Disruption of negative feedback example: When Ras oncoprotein is mutated, Ras GTPase activity is conditioned and 
signalling proliferative pathway affected, enhancer the proliferation.  
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1.1.1.2 Evading Growth Suppressors 
 
 Normal tissues control the production and release of growth suppressors by two 
mechanisms: induction of the G0 phase and induction of a post-mitotic state, usually 
related with differentiation of the cell (14). However, cancer cells have the ability to 
circumvent the regulated cell proliferation programme (13).  
 In cancer cells, the two tumour suppressors most commonly dysregulated are 
the retinoblastoma protein (Rb) and p53 (13). Rb is responsible for inhibiting cell passage 
through the restriction point in the G1 cell-cycle phase; in cancer cells, Rb is mutated, 
moving this restricting point and, consequently, allowing cell proliferation (14,16). p53 
activation occurs towards DNA damage or oncogene activation, resulting in G1 cell cycle 
arrest and apoptosis; if this activation does not occur, cellular proliferation continues, 
despite any damage or error (17).  
  
 
1.1.1.3 Resisting Cell Death 
 
 Apoptosis is a highly conserved mechanism responsible for maintaining cell 
number and tissue homeostasis. This mechanism is controlled by a complex regulatory 
network containing pro-apoptotic (Bax and Bak), which enhances the expression and is 
in charge of the apoptotic cascade and anti-apoptotic regulatory molecules that regulate 
anti-apoptotic factors (e.g.: NF-κB, AKT, Bcl-2 and IAP family of proteins) (13,18,19). This 
mechanism is delicately regulated and balanced by physiological features, characterized 
by cell membrane blebbing, cell shrinkage, nuclear fragmentation, chromatin 
condensation and chromosomal DNA fragmentation (19). 
 Apoptosis occurs through two major pathways: the intrinsic and extrinsic 
pathways. The intrinsic pathway (or the mitochondrial pathway) is activated by intrinsic 
signals including DNA damage induced by radiation or chemicals, growth factor 
deprivation or oxidative stress, resulting in the formation of a complex – apoptosome – 
composed of procaspase-9, apoptotic protease activating factor and cytochrome c. The 
release of cytochrome c is regulated by Bcl-2 family members (e.g.: Bax, Bak, Bcl-2 and 
Bcl-XL) through mitochondrial membrane permeabilization. The extrinsic pathway (or 
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death receptor pathway) is initiated by apoptotic stimuli mediated by cell surface death 
receptors such as Fas ligand, TNF-related apoptosis inducing ligand (TRAIL) and TNF-α 
(18).  
In cancer situations, cancer cells can develop resistance to apoptosis by two 
different ways: up-regulation or over-activation of anti-apoptotic proteins or down-
regulation of pro-apoptotic proteins (19). One example is the influence of p53 in 
apoptosis: in normal cells, p53 induces apoptosis by up-regulating the expression of the 
Noxa and Puma BH-3-only proteins, in response to substantial levels of DNA breaks and 
chromosome abnormalities (Fig. I-6). However, in cancer cells, the loss of p53 tumour 
suppressor function eliminates this critical damage sensor from the apoptosis-inducing 
circuitry (13).  
 
  
 
Figure I-6. p53 apoptotic pathway (20). 
In the cytosolic p53 apoptotic pathway, nuclear p53 induces Puma expression, which releases inactive cytosolic p53 
in the cytoplasm through binding to Bcl-XL, inducing Bax oligomerization and mitochondrial translocation. In the 
mitochondria, p53 induces Bax and Bak oligomerization, antagonizes the Bcl-2 and Bcl-Xl antiapoptotic effect and 
forms a complex with cyclophylin D in the mitochondrial inner membrane. These changes result in marked disruption 
of mitochondrial membrane and subsequent release of soluble and insoluble apoptogenic factors.  
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Besides apoptosis, there are other mechanisms that regulate cell death such as 
cell-to-cell contacts, the recognition and destruction of the cancer cells by the immune 
system, autophagy, phagocytosis and necroptosis (18). The role of autophagy and 
necroptosis, however, is not consensual since some articles refer advantages to cancer 
cells through these mechanisms; autophagy is apparently cytoprotective for cancer cells 
and necrosis can activate tumour promoters and recruit tumour promoting 
inflammatory cells (13).  
 
 
1.1.1.4 Enabling Replication Immortality  
 
 Normal cells have a limited number of successive cell growth and division cycles, 
which are controlled by senescence (irreversible non-proliferative but viable state of 
cell) and crisis (process of cell death). This limited number of division cycles is regulated 
by telomeres: telomeres are composed of hexanucleotide repeats, which get shortened 
progressively in non-immortalized cells, losing the ability to protect the end of 
chromosomal DNA from end-to-end fusions. In non-immortal cells, telomerase – a DNA 
polymerase that adds telomere repeat segments to the end of telomeric DNA – is almost 
absent. However, when telomerase is active, cells develop resistance to induction of 
senescence and crisis/apoptosis, resulting in continuous cell proliferation and cancer 
development (Fig. I-7) (13).  
 
 
 
 
 
 
 
 
 
 
 
Figure I-7. Enabling replicative immortality (15). 
In normal cells, shorten telomeres activate replicative senescence while in cancel cells, telomerase is active, 
resulting in telomere length maintenance and cell immortality.  
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1.1.1.5 Inducing Angiogenesis  
 
All cells require nutrients and oxygen supply as well as metabolic wastes and 
carbon dioxide removal; requirements provided by the normal vasculature of cells. In 
cancer situations, the higher number of cells requires an amplified vasculature of cancer 
cells through a process named angiogenesis (13).  
Angiogenesis is the sprouting of new blood vessels from already established 
vessels; it is a complex multistep process that follows stage and tissue specific 
regulations (21). This process (angiogenesis switch) occurs in an early state of cancer 
development and is regulated by signalling proteins that bind to stimulatory or 
inhibitory cell-surface receptors displayed by vascular endothelial cells (e.g. vascular 
endothelial growth factor (VEGF), as inducer; and thrombospodin-1 (TSP-1), as inhibitor) 
(13).   
Besides these receptors, pericytes and bone marrow derived cells are also an 
important part of angiogenesis. Pericytes are supporting cells that, in a normal situation, 
provide mechanisms and physiologic support to endothelial cells; in a cancer situation, 
pericytes maintain a functional tumour neovasculature. Bone marrow derived cells such 
as macrophages, neutrophils, mast cells and myeloid progenitors, infiltrate 
premalignant lesions, aiding the progression of tumours and sustaining angiogenesis 
(13).   
 
 
1.1.1.6 Activating Invasion and Metastasis   
 
The word metastasis refers to a multistage process during which cancer cells 
spread from the primary tumour to discontiguous organs (22). There are some 
prerequisites to allow such process: unlimited proliferation of cells, evasion of cell-
intrinsic and environmental constraints, attraction of blood supply, and capacity to 
detach and move away from the original location (23).  
The metastasis process consists of interrelated and sequential steps including: i) 
transformation of initial cells and progressive and slow neoplastic growth; ii) 
vascularization for tumour and synthesis and secretion of angiogenic factors; iii) local 
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invasion of the host stroma by tumour cells; iv) detachment and embolization of tumour 
cell aggregates; v) circulation of these emboli within the vascular, hematologic and 
lymphatic systems; vi) survival of tumour cells in circulation and arrest in capillaries; vii) 
extravasation of the tumour cells resulting in metastasis; viii) proliferation of tumour 
cells in a new organ; ix) establishment of vascularization and defences against host 
immune responses; x) re-initiation of metastasis process, developing metastases from 
metastases (Fig. I-8 ) (22).   
 
 
Figure I-8. The sequential process of metastasis (22). 
 
 Some of the cell alterations in metastasis situation include: 
- Decrease of cell-to-cell adhesion capacity through E-cadherin (high values of E-
cadherin induce an antagonist of invasion metastasis due to high cell to cell adhesion) 
and N-cadherin (associated with cell migrations; high values correspond to invasive 
carcinomas); 
- Epithelial-mesenchymal transition – ability of transformed epithelial cells to 
invade tissues, to resist apoptosis and to disseminate to other tissues;   
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- Contribution of stroma cells - tumour-associated macrophages (TAM) supply 
epidermal growth factor (EGF) while cancer cells stimulate macrophages with colony-
stimulating factor 1 (CSF-1) (Fig. I-9) (13).  
 
Figure I-9. Activating invasion and metastasis (15). 
Process focus on stroma cells: macrophages stimuli epidermal growth factor (EGF) receptor of tumours cells while 
cancer cell stimuli macrophage with colony-stimulating factor 1 (CSF-1).  
 
   
1.1.1.7 Deregulating Cellular Energetics   
 
Cellular metabolism is essential to cells since it provides energy through the 
supply of adenosine triphosphate. This energy is used in functions such as DNA 
replication, transcription, translation, protein transport, assembly of multi-molecule 
complex and organelles, cell mobility and enzymatic reactions (24). 
When cells suffer metabolic transformation, there are some alterations that 
contribute to oncogenes or tumour suppressors origin, namely: increase of glycoses 
consumption, decrease of mitochondrial respiration and increased production of 
reactive oxygen species (ROS). Based on these alterations, when normal cells turn into 
cancer cells, they can present different phenotypes (25):  
1) Apoptosis resistance (25); 
2) Increased anabolic activity, supporting uncontrolled growth and proliferation 
(25); 
3) Increase ROS production, activating metastatic proteases, tumour-
promoting inflammation, gene instability and DNA mutagenesis (25);  
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4) Mitochondrial oxidative phosphorylation (OXPHOS) decrease, increasing 
aerobic glycolysis and decrease of extracellular pH (25).  
 
In normal situations, when cells are under aerobic conditions, they process 
glucose to pyruvate, via glycolysis in the cytosol, and then to carbon dioxide in the 
mitochondria. Under anaerobic conditions, glucose is preferentially processed via 
glycolysis and little pyruvate is used by mitochondria. Cancer cells process glucose 
almost always via aerobic glycolysis, even under hypoxic conditions (The Warburg 
effect). Thus, energy production in cancer cells is adjusted by reprogramming glucose 
metabolism, up-regulating glucose transporters (Glucose Transporter 1 – GLUT1) and 
depend on alternate metabolic pathways (13).  
 
 
 
Figure I-10. Summary of altered mitochondrial functions in cancer cell life and death (25). 
a) Normal non-transformed cells; b) Normal cells sensitive to apoptotic stimuli; c) Cancer cells with altered 
metabolism (gain-of-function of oncogenes and loss-of-function of tumour suppressor genes); d) Cancer cells with 
cancer death resistance.  
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 Figure I-10 describes the different situations that can affect cellular metabolism, 
in cancer cells life and death:  
a) In normal situations, and aerobic conditions, cells process glucose through the 
glycolysis pathway: glucose is metabolized to pyruvate, entering the mitochondrial TCA 
Cycle (tricarboxylic acid cycle, or Krebs cycle) and producing reduced equivalent and 
adenosine triphosphate (ATP), through OXPHOS (25). 
b) In normal cells sensitive to apoptosis stimuli, Bax/Bak are activated and MOMP 
(mitochondrial outer membrane permeabilization) releases cytochrome c into the 
cytosol, stimulating the formation of apoptosome and apoptotic cell death (25). 
 c) In cancer cells, glucose is degraded by glycolysis and the resulting pyruvate is 
reduced to lactate to generate ATP. These cells have the ability to reprogram glucose 
metabolism and upregulate glucose transporters (GLUT1), having a low OXPHOS activity 
and increased mitochondrial ROS production (25). 
Altered genes such as MYC, HIFα (Hypoxia-inducible factor) and p53 are 
examples of altered metabolism by the Warburg effect. MYC is an oncogene activated 
in cell progression, apoptosis and cellular transformation. MYC induces transcription of 
metabolic enzymes required for anabolism and fast cell growth, regulates the 
conversion of glucose to pyruvate through glycolysis genes and glucose transporters, 
and blocks the entry of pyruvate into the TCA cycle. That is, MYC is responsible for the 
metabolic adaptation of tumour cells. p53, when lost, increases the glycolytic flux to 
promote anabolism and redox balance while H1Fα promotes the conversion of glucose 
to pyruvate and lactate by up-regulating GLUT-1 and other transporters, decreasing the 
conversion of pyruvate to Acetyl-CoA, which compromises OXPHOS (25,26). 
 d) Cancer cells resistant to cell death present anti-apoptosis proteins or 
inactivated pro-apoptotic proteins that counteract Bax/Bak and MOMP (described in 
b)). In addition, mitochondrial cholesterol loading shields mitochondrial membrane and 
impairs Bax/Bak and MOMP (25). 
 
 The major problem of the described metabolic alterations is probably the 
production of reactive oxygen species. ROS promote tumour growth, angiogenesis and 
metastasis. Due to their higher reactivity, ROS induce DNA damage, transforming normal 
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cells into cancer cells. However, there is no consensus about the use or not of anti-
oxidants in anticancer therapies. If, on one hand, there are some evidences of the 
reduction of cancer risk development and slow cancer progression due to the use of 
anti-oxidants, on another hand, there are evidences of cancer cells adaptation to these 
compounds, developing strategies of proliferation (25). 
 
 
1.1.1.8 Avoiding Immune Destruction   
 
The immune system plays an important role in preventing the formation and in 
fighting neoplastic cells. In fact, there are some evidences that the deficient 
development of CD8+ cytotoxic T lymphocytes, CD4+ Th1 helper T cells or natural killer 
(NK) cells increases tumour incidence (13). 
The cancer immune-editing process (a process of the immune system that 
impedes tumour growth and progression) is classified in three phases named the “three 
Es”: elimination, equilibrium and escape. The elimination (or protection) phase refers to 
the recognition and elimination of cancer cells by the immune system, returning tissues 
to normal conditions. The equilibrium phase (or persistence phase) is poorly 
understood; in this phase, the immune system controls tumour growth without 
eliminating the transformed cells. In the third phase, the escape phase (or progression), 
tumours are no longer susceptible to the immune system, being able to use in their 
advantage enhancing tumour cell growth (27,28). 
Figure I-11 illustrates the immune-editing process. In the first phase, elimination 
phase, the immune system (innate and adaptive) proceeds to the recognition of 
transformed cells. Natural killer cells, CD4+ and CD8+ T cells recognize tumour cells, 
allowing the immune system to kill them and through the production of chemokines and 
other cytokines that facilitate the process. If tumour cells are not killed in the first phase, 
the immune system prevents their development. The escape phase consists on tumour 
cells, which evade the immune pressure of the equilibrium phase, tumour cell variants 
(tumour cells that suffer immune selection pressure, being resistant to the immune 
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effector cells) and non-immunogenic transformed cells. This phase is clinically 
detectable and allows the progression of tumours (28,29).   
 
 
Figure I-11. Cancer immune-editing (28). 
BRCA (Breast cancer, early onset); ECM (extracellular matrix); IDO (indoleamine 2,3-dioxygenase); IFN (interferon); 
MIC (MHC-class- I-polypeptide-related sequence); NK (natural killer); NKT (natural killer T); p53 (tumour-suppressor 
protein p53); RAE1 (retinoic acid early transcript 1); Rb (retinoblastoma protein); TRAIL (tumour-necrosis-factor-
related apoptosis-inducing ligand); TReg (CD4+CD25+ regulatory T); ULBP (cytomegalovirus UL16-binding protein). 
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  1.1.1.9 Genome Instability and Mutation   
 
Genome instability plays an important role in cancer development since it can 
manifest during all the cancer process. Additionally, mutated genotypes represent a 
selective advantage since it allows the growth and proliferation of cancer cells in normal 
tissues (13,30). 
The most relevant pathways that affect genomic instability include telomere 
damage, centrosome amplification, epigenetic modifications and DNA damage. 
Telomeres are located in the end of a chromosome and function as protective caps used 
by the cells to control cellular division, guiding the cell to cellular death. Centromeres 
are the primary microtubules used in mitoses to allow an equal division of the genetic 
material. Epigenetic modifications refer to heritable changes of the primary DNA 
sequence without changing itself while DNA damage can be cause by diverse pathways, 
as already mentioned (30). 
 DNA maintenance machinery, also named caretakers, has a relevant work in this 
hallmark and complements the work of the cellular constituents described in the 
previous paragraph. These caretaker genes are responsible for the detection and repair 
of damage DNA, direct repairing of damage DNA and inactivation or interception of 
mutagenic molecules before DNA damages (13).  
 Based on the mechanisms that influence genomic instability, it is possible to 
define some targets: prevention of DNA damage; improvement of DNA repair; signal of 
DNA repair weakness; impairment of centrosome clustering; inhibition of telomerase 
activity (30). 
 
 
1.1.1.10 Tumour-Promoting Inflammation   
 
Towards cancer development, there are some conditions that could be modified 
and contribute to cancer proliferation. The set of all these modifications - Tumour 
Microenvironment (TME) - consists in the interactions between malignant and non-
malignant cells, sustaining the growth, invasion and metastasis processes (31,32). 
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Tumour Microenvironment contains different kinds of cells, including malignant 
cells, cell of the immune system, tumour vasculature and lymphatics, fibroblasts, 
pericytes and adipocytes, which are responsible for the complex communication 
between these cells through cytokines, chemokines, growth factors and inflammatory 
and matrix remodelling enzymes (Fig. I-12) (31). These include: 
- T Lymphocytes - cytotoxic CD8+ memory T cells, able to kill tumour cell; CD4+ 
T helper 1 (TH1) cells, responsible for the production of interleukin-2 (IL-2) and 
interferon gamma (IFN-γ); TH2 cells, that produce IL-4, IL-5 and IL-3), supporting B cell 
responses; TH17 cells promote tumour growth through tissue antibacterial 
inflammation mediated by IL-17A, IL-17F, IL-21 and IL-22;  immunosuppressive T 
regulatory cells (Treg) are immunosuppressed by CD4+, inhibiting the recognition and 
clearance of tumour cells by the immune system (31). 
- B Lymphocytes - more frequently found in draining lymph nodes and 
lymphoid structures (31). 
- Natural killer and natural killer T cells - both cells are not found in contact with 
cancer cells and NK do not exert tumour-killing function (31). 
- Tumour-associated macrophages - these cells exhibit a pro-tumorigenic 
activity, being the major contributor to tumour angiogenesis. TAMs tend to accumulate 
themselves near cells in hypoxia and/or necrosis, probably due to hypoxia-induced 
chemo-attraction (31). 
- Myeloid-derived suppressor cells - increased in cancer situations, these cells 
inhibit immune cells (31). 
- Dendritic Cells (DCs) - antigen processing and presentation function. It is 
thought that the activity of DCs in the TME is defective, in other words, cannot perform 
the stimulation of the immune to tumour-associated antigen (31). 
- Tumour-associated neutrophils – their contribution is controversial.  In spite 
of existing some evidences that neutrophils are involved in mechanisms such as tumour 
growth promotion and immune suppression, neutrophils are also involved in tumour 
cells destruction and inhibition of TGF-β (31). 
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- Cancer-associated fibroblasts (CAFs) - myofibroblasts that secret growth and 
pro-inflammatory factors as well as induce vascular permeability and angiogenesis 
(31,32). 
- Adipocytes - these cells collaborate in the recruitment of tumour cells and 
provide fatty acids required for cellular growth (31). 
- Vascular endothelial cells - in association with pericytes, these cells contribute 
to the neovascularization of tumours (31). 
- Pericytes - cells that provide structural support to blood vessels (31).  
- Lymphatic endothelial cells - cells with an important role in malign cells 
dissemination (31). 
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Figure I-12. The Tumour Microenvironment (31). 
TME constists on the presence of different cells and their products, which contribute to cancer development through the supply of proliferative conditions. This 
figure illustrats these cells and their influence.  
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1.1.2 Leukaemia and Lymphomas 
 
The WHO refers a total of 14.1 million new cases of cancer and 8.2 million deaths 
in 2012, as mentioned before. From all the new cancer cases, 2.5% were leukaemia and 
3.2% were lymphoma (Hodgkin and Non-Hodgkin). The low survival ratio (compared to 
the number of deaths / new cases, in 2012) - 25% for leukaemia and 50% for lymphoma 
- justifies the necessity to develop new drugs and to improve current treatments (6). 
 
 
1.1.2.1 Leukaemia   
 
 Blood consists of a wide variety of cells: erythrocytes, also known as red blood 
cells, which are responsible for the oxygen transport; platelets that are involved in blood 
clotting; and leukocytes, or white blood cells, that play an important role in immune 
response. All these cells have a common characteristic: they originate from the myeloid 
pathway of haematopoiesis process, having a common progenitor cells, hematopoietic 
stem cells. Due to external pressures and different cell conditions, when leukocytes stem 
cells suffer abnormal modifications, they turn into cancer cells – Leukaemia (33,34). 
Leukaemia’s classification is based on four characters:  onset (acute or chronic), 
affected blood cell type (lymphoblastic/lymphocytic or myeloid/myelogenous), maturity 
stage and phenotypic expression (34). Thus, there are 4 major types of leukaemia:  
- Acute myeloid leukaemia (AML); 
- Chronic myeloid leukaemia (CML); 
- Acute lymphoblastic leukaemia (ALL); 
- Chronic lymphocytic leukaemia (CLL). 
 
Leukaemia symptoms are common to the different types of the disease and 
include fever, fatigue, weakness, loss of appetite and weight loss, night sweats and 
frequent infections. Leukaemia incidence depends on the type of leukaemia: ALL is more 
common in childhood, when CLL affects predominantly older adults; AML is common in 
children and adult while CML affects adults (35). 
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Table  I-2. 2016 WHO classification of mature lymphoid, histiocytic and dendritic neoplasm. (73) 
In 2016, WHO revised the previous classification of hematopoietic and lymphoid tumours, published in 2008. 
 
1.1.2.2 Lymphoma   
 
 According to the WHO classification system, there are more than 50 distinct 
lymphomas classified in two big types: Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL) 
(Table I-2) (36).   
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The etiology of Lymphomas remains unknown but there are some factors that 
seem to influence this disease’s development; the Epstein-Barr virus, autoimmune 
conditions and human immunodeficiency virus (HIV) are frequently present in patients 
who suffer Lymphoma disease. Certain industrial products, such as pesticides and hair 
dyes prior to 1980 appeared also to be related with some Lymphoma cases (36).  
 
Hodgkin Lymphoma 
 
 Hodgkin lymphoma consists in a malignant transformation of a germinal or post-
germinal centre B cell, presenting a small number of Reed-Sternberg cells (large and 
multi-nucleated tumour cells of HL that derived from pre-apoptotic germinal centre B 
cells, losing their B cell identity) (36,37). 
 During the last years, the cellular origin of Hodgkin Lymphomas has been 
clarified. Due to the silencing of regulators of B cell differentiation (ABF-1, ID2 and 
NOTCH1, for example) or the disruption of B-cell specific gene expression (BCL6, 
NOTCH1 inhibition, for example), Reed-Sternberg cells, the tumour cells of HL, seem to 
result from a defect in the cytokinesis of cells. Some mechanisms responsible for 
Hodgkin-Reed-Sternberg cells include NF-κB activity encouraged by TNF/death-receptor 
family members, constitutive IκB kinase (IKK) complex and NF-κB inducing kinase (NIK). 
The disruption of JAK/STAT Signalling (Janus kinase/signal transducers and activators of 
transcription pathway) and deregulation of the AP-1/CREB complex are other drivers to 
HL pathology (38). 
The clinical manifestations expressed include symptomatic lymphadenopathy, 
mediastinal mass and systemic symptoms (fever, weight lost, sweats) (39). 
 
Non-Hodgkin Lymphoma 
 
Non-Hodgkin Lymphoma (NHL) is characterised by the presence of a group of 
malignant cells derived from B cells (most common), T cells, Natural killer cells and their 
precursors. Non-Hodgkin Lymphoma differs from Hodgkin Lymphoma since Reed-
Sternberg cells are not present (40). 
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The most common NHL are Diffuse large B cell lymphoma (DLBCL), Mantel cell 
lymphoma, Burkitt lymphoma (BL), Chronic lymphocytic leukaemia / Small lymphocytic 
lymphoma (CLL/SLL), Follicular lymphoma (FL) and Marginal zone lymphoma (MZL). The 
classification in these subtypes is based on the cell of origin, namely morphologic, 
immunophenotypic and genetic features of the malignant cells, as illustrated in Fig. I-22 
(41). 
The clinical manifestations of NHL depend if we are in the presence of aggressive 
or indolent lymphomas. Aggressive lymphomas (DLBCL and BL, for example) are 
characterised by systemic B symptoms (fever, night sweats, weigh loss), an increase of 
lactate dehydrogenase and uric acid concentration as well as a rapidly growing mass. 
Indolent lymphomas (CLL/SLL, FL and MZL) cause a slow growing lymphadenopathy, 
splenomegaly, hepatomegaly and cytopenias (40). 
 
Figure I-13. Schematic Non-Hodgkin Lymphoma cells development and respective mechanisms (41). 
Ag: antigen; CLL/SLL: Chronic lymphocytic leukaemia / Small lymphocytic lymphoma; GCB DLBCL: germinal centre B 
cell diffuse large B cell lymphoma; FL: follicular lymphoma; MZL: marginal zone lymphoma; ABC DLBCL: activated B 
cell diffuse large B cell lymphoma; MM: multiple myeloma.  
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 1.1.3 Actual therapies: mechanisms and adverse effects 
 
There are different modalities for cancer treatment: surgery, radiation, 
chemotherapy and biologic therapy (2). This work only focuses on chemotherapy 
treatment.  
 
Cancer chemotherapeutic drugs can be classified as alkylating agents, 
antimetabolites, natural products cancer chemotherapy drugs, antitumor antibiotics or 
miscellaneous anticancer drugs (42). 
Alkylating agents (Fig. I-14) exercise their anticancer activity through the transfer 
of alkyl groups to different constituents of the cell, causing the cross-linking of DNA 
strands. There are three characteristic mechanisms such as DNA cross-links with 
consequently inhibition of DNA synthesis and functions (e.g.: mechlorethamine (a), 
carmustine (b) (nitrosourea), busulfan (c)); DNA methylation with DNA synthesis and 
function inhibition (e.g.: procarbazine (d)) and DNA intra and inter-strand cross link in 
nucleous and cytoplasmic proteins (nitrosoureas: cisplatin (e), carboplatin (f) and 
oxaliplatin (g)) (42).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALKYLATING AGENTS 
a) Mechlorethamine 
 
b) Carmustine 
 
c) Busulfan 
 
 
d) Procarbazine 
 
e) Cisplatin 
 
 
f) Carboplatin
 
g) Oxaliplatin 
 
Figure I-14. Chemical structure of alkylating agents (44). 
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Antimetabolite drugs (Fig. I-15) are compounds with structural similarities to 
metabolites competing with the same enzymes to inhibit nucleotide biosynthesis and 
cell death (43). This class of drugs includes the antifolates like methotrexate (h), 
fluoropyrimidines like 5-fluorouracil (i), deoxycytidine analogues like cytarabine (j) and 
purine antagonists like 6-mercaptopurine (k) (42). 
 
 
Figure I-15. Chemical structures of antimetabolites (44). 
 
 
Natural products cancer chemotherapy drugs (Fig. I-16) are divided in vinca 
alkaloids, taxanes and related drugs, epipodophyllotoxins and camptothecins. Vinca 
alkaloids (vinblastine (l), vincristine (m) and vinorelbine(n)) inhibit mitosis through 
tubulin polymerization. Taxanes and related drugs like paclitaxel (o) also act in mitosis 
inhibition. Etoposide (p), an epipodophyllotoxin, inhibits the DNA enzyme 
topoisomerase II while camptothecins like topotecan (q) and irinotecan (r) inhibit 
topoisomerase I (42). 
 
ANTIMETABOLITES 
h) Methotrexate 
 
i) 5-Fluorouracil 
 
j) Cytarabine 
 
k) 6-Mercaptopurine 
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Figure I-16. Chemical structures of natural products used in chemotherapy (44).  
 
 
 
NATURAL PRODUCTS 
l) Vinblastine   
m)  Vincristine
 
 
 
n) Vinorelbine 
 
o) Paclitaxel 
 
p) Etoposide 
 
 
 
q) Topotecan 
r) Irinotecan 
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Antitumor antibiotics (Fig. I-17) include anthracyclines (doxorubicin (s), for 
example), which inhibit topoisomerase II, intercalate into DNA and release oxygen free 
radicals that cause DNA breaks. Mitomycin (t) and bleomycin (u) are also antitumor 
antibiotics, which act by an alkylating mechanism and act as oxygen free radicals’ 
releaser, respectively (42).  
 
 
 
Figure I-17. Chemical structures of antitumoural antibiotics (44).  
 
ANTITUMOURAL ANTIBIOTICS 
s) Doxorubicin 
 
 
t) Mitomycin 
 
u) Bleomycin 
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The last drug classification, miscellaneous anticancer drugs, includes various 
types of drugs: imatinib (v), dasatinib (w) and nilotinib (x) (inhibitors of tyrosine kinase 
domains of the BCR-ABL oncoprotein, platelet-derived growth factor receptors, stem 
cell factor and c-kit), growth factor receptor inhibitors (inhibitors of epidermal growth 
factor receptor signalling and vascular endothelial growth factor which lead to 
angiogenesis, invasion and metastasis inhibition) and asparaginase (exogenous source 
of L-asparagine amidohydrolase) (42).   
 
 
Figure I-18. Chemical structures of miscellaneous anticancer drugs (44).  
 
Despite the existence of different drug mechanisms, all of them present side 
effects, the most common being: nausea, vomiting, diarrhoea, fatigue, 
myelosuppression, neutropenia, thrombocytopenia, hepatotoxicity, alopecia, mucositis, 
among others (45). 
 
In addition, tumour cells have the ability to adapt to adverse conditions provided 
by anticancer drugs through resistance drug mechanisms such as: i) mutations in the 
target; ii) reactivation of the targeted pathway; iii) hyperactivation of the alternative 
pathway; iv) cross-talk with the microenvironment; v) clonal evaluation (46).  
MISCELLANEOUS ANTICANCER DRUGS 
v) Imatinib 
 
 
w) Dasatinib 
 
 
 
 
x) Nilotinib 
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1.1.4 New Approaches to Therapy  
 
The existence of side effects and the development of tumour resistance, 
associated with the necessity of more specific anticancer drugs amply justify the 
necessity for new drugs able to improve the efficacy and reduce the toxicity of 
therapeutics.  
 Table I.3 presents some of the new agents that are being developed in the acute 
myeloid leukaemia field.  
 
Table  I-3. New agents for the treatment of Acute Myeloid Leukaemia (adapted from(47,48)). 
Agent Mechanism of action 
CPX-351 Liposomal formulation of cytarabine + daunorubicin in 5:1 molar ratio 
Vosaroxin Novel topoisomerase II inhibitor 
Guadecitabine 
Hypomethylating agent resistant to 
deamination 
SGN-CD33A Antibody-drug conjugate against CD33 with stable linker 
Volasertib Novel PLK1 (polo-like kinase 1) inhibitor 
Quizartinib FLT3 inhibitor 
Crenolanib 
FLT3 inhibitor with activity against 
TKD (tyrosine kinase domain) -resistance mutation 
ASP-2215 
FLT3 inhibitor with activity against 
TKD-resistance mutation 
AG-221 IDH2 inhibitor 
AG-120 IDH1 inhibitor 
EPZ-5676 DOT1L inhibitor 
ABT-199 BCL2 inhibitor 
OTX-015 BET (bromodomain) inhibitor 
Pracinostat HDAC (histone deacetylase) inhibitor 
Sorafenib Tyrosine kinase inhibitor (TKI) 
Midostaurin FLT3 TKI 
STAT inhibitors STAT3 tyrosine phosphorylation 
Clofarabine Purine nucleoside analog 
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1.2 Bis-indolyl Methanes 
 
Bis-indolyl methane (BIM), also known as 3,3-di-indolylmethane (DIM), is a 
natural metabolite of indole-3-carbinol that occurs in Brassica genus plants (cruciferous 
plants): broccoli, brussels sprouts, cauliflower, kale and cabbage (49–51). 
BIM have different biological activities described, such as antibacterial, 
antifungal, analgesic, anti-inflammatory, anthelmintic, cardiovascular and, the most 
important to our study, anticancer activity (52). Besides these, BIM is also described as 
a colourimetric and ratiometric chemosensor for Cu2+ (53). 
Exploring the anticancer activity, it is possible to find studies about BIM’s activity 
in breast, cervical, ovarian, colon, hepatoma and prostate cancer (54–59). 
 
 
1.2.1 Structure of Bis-indolyl Methanes  
 
Bis-indolyl methane is composed by two indole molecules (pharmacophores), 
which are responsible for the anticancer activity of some drugs, attached to a methane 
group.  
 
 
 
 
 
 
 
 
The indole group is characteristic of anticancer groups as vinca alkaloides 
(vincristine, vinblastine, vinorelbine, vindesine) (60). 
 
 
Figure I-19. Bis-indolyl methane structure. 
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1.2.2 Tumour anti-progression activity of Bis-indolyl Methanes 
 
As mentioned before, there are different biological activities described to BIMs, 
namely anticancer activity, and different mechanisms of action associated: 
- Breast Cancer: Some articles refer BIMs as inhibitors of proliferation (estrogen-
dependent and non-estrogen dependent cells), inducing apoptosis by 
decreasing Bcl-2 levels and increasing Bax and Bax/Bcl2 ratio levels; inductors 
of G1 cell cycle and p21 gene expression; up-regulators of interferon γ 
expression; inhibitors of Akt, NF-κB and mTOR (51,57,61). 
- Cervical Cancer: MAPK (Mitogen-activated protein kinases) and PI3K pathways 
are modified by BIMs interference (62). 
- Ovarian Cancer: BIMs inhibit the signal transducer and activator of 
transcription pathway (STAT) through the anti-IL6 activity. Thus, cancer cell 
proliferation processes (adhesion, migration and invasion) are inhibited too 
(55). 
- Colon Cancer: treatments with BIM showed a significant reduction of c-Myc, 
β-catenin and cyclin D1 protein levels, which are important oncogenes, by 
inactivation of β-catenin and targeting the Wnt/ β-catenin signalling pathway, 
as well as induction of G1 phase (63). Another study concluded that class I 
histone deacetylases are selectively induced by BIM, increasing p21 and 27 
expressions and causing DNA damage and consequently apoptosis (64). 
- Hepatoma Cancer: BIMs present an inhibitor activity against topoisomerase IIα 
and topoisomerase I and Iiβ (partial inhibition), which block DNA synthesis and 
mitosis processes (58). Phosphorylation of FAK and Estrogen signalling 
pathway mechanisms contribute to inhibition of cell proliferation and 
induction of tumorigenesis, respectively (65). 
- Prostate Cancer: PI3K and Akt seems to be inhibited by BIMs (61). NF-κB, VEGF, 
Androgen receptor signal, uPA/uPAR (Urokinase receptor), MAPK (Mitogen-
activated protein kinases) pathway and p75 (prostate epithelial cells tumour 
suppressor) are also subject to BIM influence (66). 
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In summary, BIMs lead to cellular apoptosis and anti-proliferation mechanisms 
through interferences in Bcl2, Bax, Akt, NF-κB pathway, mTOR STAT, Wnt/ β-catenin 
signalling pathway, VEGF, among other processes. BIM is also involved in reactive 
oxygen species production and cellular endoplasmatic reticulum stress, which cause 
DNA damage and consequently apoptosis (65). 
 
 
1.3 Structure-activity relationship 
 
During the drug development process, many steps are involved: drug discovery, 
drug design and drug development. Drug discovery includes the choice of the study 
disease as well as the drug target and the lead compound; drug design consists of the 
identification of structure-activity relationship (SAR) and the pharmacophore and on the 
improvement of pharmacodynamic and pharmacokinetic properties. Drug development 
includes pre-clinical and clinical trials (44). 
Due to limited resources and limitations in experimental animal use, the 
investigation of new chemical compounds became too costly and time consuming (67). 
Thus, the development of structure-activity relationship and in silico studies, both 
computer models, became crucial to drug development.  
Structure-activity relationship intents to obtain a statistical model of the 
compound activity considering its physicochemical properties and biological activities. 
SAR takes into account parameters as: ligands and their binding sites, inhibition 
constants, rate constants, lipophilicity, polarizability, electronic and steric properties; 
and allows relating chemical structure to qualitative biological activity, avoiding the 
experimental part of non-active compounds (67,68). 
In silico studies are used to discover and optimize novel molecules with affinity 
to a target, to test ADMET properties (adsorption, distribution, metabolism, excretion 
and toxicity) and to characterize physicochemical properties. These studies include 
databases, quantitative SAR, pharmacophores, molecular modelling approaches and 
analysis tools (69,70).  
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1.3.1 Bis-indolyl Methanes in Cancer 
 
The article Novel approach to bis(indolyl)methane: De novo synthesis of 1-
hidroxyminomethyl derivatives with anticancer properties studied the influence of this 
compound in leukaemia and lymphoma cells.  In this study, it was possible to conclude 
that (E)-1-((4-bromophenyl)-1-hydroxyiminomethyl)bis(1H-indol-3-yl)methane 
(henceforth designed as 9a), was worth pursuing due to its lower half maximal inhibitory 
concentration (IC50) and higher selectivity. In this context, different compounds were 
chemical synthetized and their biological activity determined in order to continue the 
work already done in this area (71).  
 
 
Figure I-20. Chemical structure of 9a ((E)-1-((4-bromophenyl)-1-hydroxyiminomethyl)bis(1H-indol-3-yl)methane).  
 
 
1.4 Aim of the thesis 
  
The number of cancer patients continues to increase, demanding for new 
anticancer therapeutics development.  
The use of BIMs is already being investigated for some cancers as breast, cervical, 
ovarian, colon, hepatoma and prostate cancer. The major goal of this work was to study 
BIMs cytotoxic activity in lymphoma and leukaemia cells.  
 The specific objectives of this work were:   
1) To study the cytotoxic activity of two classes of compounds of new bis-indolyl 
compounds (oximes and hydrazones) in four different cell lines - S17 (murine bone 
marrow), THP1 (human acute monocytic leukaemia), U937 (human leukaemic 
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monocytic lymphoma) and EL4 (murine T-lymphoma) – using the MTT colorimetric 
assay;  
2) To relate the compounds’ chemical structure with the cytotoxic activity;  
3) To compare the effects of the studied compounds with drugs that are currently 
being used to treat cancer.  
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II. MATERIALS AND METHODS 
 
 
2.1 Chemicals, culture media and supplements 
 
Dimethyl Sulfoxide (DMSO) was purchased from Merck while Sigma-Aldrich 
(Germany) supplied 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide 
(MTT). Dulbecco’s Modified Eagle’s Medium (DMEM), Roswell Park Memorial Institute 
(RMPI) 1640 medium, foetal bovine serum, trypsin, L-glutamine and 
penicillin/streptomycin were provided by Lonza (Belgium). Additional reagents and 
solvents were obtained from VWR International (Belgium).  
 
 
2.2 Study compounds 
 
 The studied compounds in this project were provided by Professor Américo 
Lemos and his PhD student Carla Grosso. All the compounds, except otherwise 
indicated, were unknown compounds and obtained by chemical synthesis via two 
consecutive Hetero Diels-Alder reactions of nitroso- or azo-alkenes with the particular 
indole. The derivatives of bis-indolyl methane: CG-99.1, CG-109, CG-141 and CG-142 
were oximes and AL-516, AL-522B, CG-92, CG-105, CG-147, CG-151 and CG-153 were 
hydrazones. All the compounds tested are listed below in Table II-1 and II-2 and 
illustrated in Annex 7.1.  
 
 
 
 
 
 
 
 
 
 
Figure II-1. One-pot synthesis of Bis-indolyl methane. 
AL-516, AL-522B, CG-92, CG-105, CG-147, CG-151 and CG-153 compounds have hydrazone groups 
while CG-99.1, CG-109, CG-141 and CG-142 compounds have oxime groups.  
 
Base     -HX 
Hydrazones Oximes 
X = Cl or Br 
Y = O or 
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Table  II-1. Derivatives of bis-indolyl methane with oxime group, as illustrated in Figure II-1.  
1 Compounds analysed in previous experiments. 
 
Compound R2 
CG-99-1 1 Br 
CG-109 OMe 
CG-141 Me 
CG-142 OH 
 
 
Table  II-2. Derivatives of bis-indolyl methane with hydrazone group, as illustrated in Figure II-1.  
1 Compounds analysed in previous experiments. 
Compound R1 R2 R’ 
AL-516 H H 
 
AL-522B H H 
 
CG-92 1 CH3 H 
 
CG-105 
 
H 
 
CG-147 H H 
 
CG-153 H OH 
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2.3 Cell culture 
 
This study used four types of cells: three cancerous cell lines (THP-1 - human 
acute monocytic leukaemia; EL-4 - murine lymphoblast; and U937 - human lymphoblast 
lung); and a non-tumoural cell line (S17 - murine bone marrow stromal). All the cell lines 
belonged to the Marbiotech Group Lab from CCMAR.  
 S17 and EL-4 cell lines were cultured in DMEM medium supplemented with 10% 
heat-inactivated foetal bovine serum, 1% L-glutamine and 1% penicillin/streptomycin. 
THP-1 and U937 cell lines were maintained in RPMI medium with the same 
supplementation of DMEM: 10% foetal bovine serum, 1% L-glutamine and 1% 
penicillin/streptomycin. All cell lines were cultured at 37°C and 5% carbon dioxide (CO2) 
atmosphere. 
  
 
2.4 Tumour anti-progression activity 
 
2.4.1 Cytotoxicity assay  
 
Cytotoxicity assay was based on the MTT colourimetric assay, described in 2.4.1.1. 
This assay was performed in 96-well microplates at a density of 5x103 cells/well 
(adherent cell lines: S17) or 1x104 cells/well (suspension cell lines: THP-1, U937 and EL-
4).   
 After incubation to allow the adherence of S17 cells, the studied compounds 
were applied (dissolved in DMSO) and incubated for 72 hours. The first test 
concentration of each compound was 100µM and, if active (<50% cell viability), lower 
concentrations were tested and the half maximal inhibitory concentration (IC50) was 
determined. Two hours before the end of the incubation time, 20 µL of MTT (5 mg/mL 
in PBS - Phosphate-buffered saline) were added and the plates returned to the 
incubator. After the 72 hours, the supernatant was removed and 150 µL of DMSO was 
added to each well. The absorbance of the produced formazan cristals was measure at 
590nm (Biotek Synergy 4).  
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 Control cells were treated with DMSO at the highest concentration used in test 
wells (0,5%) and etoposide, a currently used cytotoxic anticancer drug, was used as a 
positive control. 
The tested compound AL-516 had the particularity of being coloured, whereby 
an additional step was necessary and a colour control containing medium and the 
compound at the same concentration as in the assay was tested. 
 The absorbance of AL-516 test samples was calculated as the difference between 
the absorbance of sample and colour control. Cell viability was determined as a ratio of 
absorbance of test sample and DMSO control (negative control) media. Results were 
expressed in terms of cell viability (%) and half maximal inhibitory concentration (IC50, 
μM).   
 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝐷𝑀𝑆𝑂 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑚𝑒𝑑𝑖𝑎
× 100 
    
% 𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (𝐴𝐿 − 516) (%)
=  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑙𝑜𝑢𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝐷𝑀𝑆𝑂 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑚𝑒𝑑𝑖𝑎
× 100 
 
 
 
2.4.1.1 MTT colourimetric assay  
 
 MTT colourimetric assay belongs to Tetrazolium Reduction Assays and consist in 
a coloured product that can be detected with a spectrophotometric plate reader (72). 
 MTT is positively charged and is able to penetrate viable cells. Viable cells have 
an active metabolism that allows the transformation of MTT into a purple coloured 
formazan product (Fig. II-3). The mechanisms of this reaction are still not well 
understood but they likely involve reactions with NADH or a similar reducing compound. 
The product of this reaction is insoluble and tends to accumulate inside cells and to 
deposit near their surface and in the culture medium. When DMSO is added, the 
formazan crystals solubilize and the solution acquire the purple colour than is measured 
in a plate absorbance reader (72). 
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Figure II-2. Structure of MTT and the product of reaction, formazan (72). 
 
 
2.4.2 Hemolytic activity  
 
 The first step of hemolytic activity determination was to remove the plasma and 
white cells from a type O blood sample (1000g, 5 minutes). After that, the appropriate 
controls and the compounds were prepared: each Eppendorf tube had 4µL of red blood 
cells and 196µL of Milli-Q water (positive control), PBS (negative control) or the tested 
compound. The different Eppendorf tubes were incubated during 1 hour at 37°C, and 
then centrifuged (1000g, 5 minutes). 100µL of each Eppendorf tube were add to a well 
(3 replicates each) and the absorbance was measured (Biotek Synergy 4).   
 The percentage of hemolysis was determined by the ratio between the 
absorbance of the sample and positive control (media).  
 
𝐻𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 (%) =  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝑚𝑒𝑑𝑖𝑎)
× 100 
 
 
2.5 Statistical analysis 
 
 The results of cytotoxicity assays where expressed in 95% confidence intervals 
and best-fit value of half-maximal inhibitory concentration, using at least six replicates, 
and were calculated using a variable slope model. Hemolytic assay results were 
compared using a one-way analysis of variance (ANOVA) and were expressed in mean ± 
SEM.  
 All the data was analysed in GraphPad Prism 6 program, version 6.01.  
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III. RESULTS AND DISCUSSION 
 
3.1 Tumour anti-progression activity 
 
3.1.1 Cytotoxicity assay and selectivity of compounds 
 
 This assay intended to study the cytotoxic activity of bis-indolyl methane 
derivatives in four cell lines, representative of three pathologic and one non pathologic 
cell lines: THP-1 (leukaemia), EL-4 and U937 (lymphoma) and S17 (bone marrow).  
 The objective was to find active compounds with cytotoxic activity towards 
cancerous cells (EL-4, THP-1 and U937) but not to non-cancerous cells (S17), in order to 
decrease the side effects of these compounds to healthy cells.  
 In a first step, all the compounds were study at 100µM. If active, the studies 
proceeded to the IC50 determination. CG-105 was the only compound not active in U937. 
All the others were active and allowed the elaboration of an IC50 curve (Annex 7.2).  
Results are summarized in table III-1.  
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Table  III-1. IC50 (µM) (Best-fit value and 95% Confidence Interval) of etoposide and BIM derivatives with oxime and hydrazone groups in suspended and non-suspended cell lines (EL-4, THP-1, 
U937 and S17).  
 
 
IC50 (µM) 
EL-4 THP-1 U937 S17 
Compound IC50 CI (95%) IC50 CI (95%) IC50 CI (95%) IC50 CI (95%) 
Etoposide 1 4,90 ± 0,47 1,82 ± 0,06 1,10 ± 0,04 17,65 ± 0,31 
B
IM
s 
d
e
ri
va
te
 
w
it
h
 o
xi
m
e
 g
ro
u
p
 CG-99-1 1 7,65 ± 1,07 12,2 ± 1,0 18,6 ± 1,1  
CG-109 9,30 (8,77 - 9,85) 22,6 (21,0 - 24,3) 18,1 (16,2 - 20,1) 17,7 (14,9 - 21,1) 
CG-141 3,23 (3,01 - 3,47) 6,34 (5,79 - 6,94) 9,79 (9,36 - 10,3) 11,5 (11,2 - 11,9) 
CG-142 15,6 (13,7 - 17,9) 15,5 (14,2 - 16,9) 12,8 (12,0 - 13,7) 21,9 (16,7 - 28,7) 
B
IM
s 
d
e
ri
va
te
 w
it
h
 h
yd
ra
zo
n
e
 
gr
o
u
p
 
AL-516 5,45 (5,20 - 5,73) 14,0 (12,2 - 16,1) 13,3 (12,0 - 14,8) 7,92 (6,88 - 9,11) 
AL-522B 18,9 (16,4 - 21,7) 23,5 (20,2 - 27,2) 22,9 (20,3 - 25,89) 58,5 (48,9 - 70,0) 
CG-92 1 9,99 ± 1,05 25,3 ± 1,1 14,2 ± 1,0  
CG-105 5,56 (5,12 - 6,05) 38,8 (31,3 - 48,2) -- 7,65 (3,95 - 14,8) 
CG-147 15,3 (13,7 - 17,1) 29,9 (24,9 - 35,8) 25,0 (23,7 - 26,4) 45,5 (42,6 - 48,6) 
CG-151 22,5 (19,6 - 25,9) 36,2 (32,5 - 40,4) 28,4 (21,3 - 37,9) 41,3 (36,9 - 46,2) 
CG-153 15,4 (12,9 - 18,4) 28,6 (24,4 - 33,5) 156 (4,83 - 5105) 39,9 (33,4 - 47,6) 
 
1 Compounds analysed in previous experiments. Results are expressed as IC50, 95% Confidence Interval or mean ± SEM; 
  -- Not active compounds at 100uM. 
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Results of IC50 showed that, in a general way, CG-141 was the most active 
compound and EL-4 was the most sensitive cell line, that means, the cell line which 
require a lower drug concentration to kill 50% or more of their population. Furthermore, 
when compared with the hydrazone derivatives, oxime derivatives had a stronger 
biological activity in these cell lines (graphic III-1). 
 
 As referred in section 1.3.3, the study of oximes continued from a previous 
investigation. In that studied, 9a structure presented an IC50 of 1.65±0.02, 1.62±0.08, 
1.64±0.08 and 16.3±0.08 µM for EL-4, THP-1, U937 and S17, respectively (71).  
 When compound 9a is compared with the oxime derivatives, it was possible to 
conclude that the hydrogen in the R2 BIM position increases the biological activity in EL-
4, THP-1 and U937.  
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Graphic III-1. Comparison between compounds and cell lines. Representation of table III.1 in order to help its interpretation.  
CG-99-1, CG-109, CG-141 and CG-142 include an oxime group in their structure. AL-516, AL-522B, CG-92, CG-105, CG-147, CG-151 and 
CG-153 consist in structures with a hydrazone group. 
 
Graphic III-2. Comparison between BIM with oxime or hydrazone group. Representation of table III.1 and III.2 in order to help in their 
interpretation.  
CG-99-1, CG-109, CG-141 and CG-142 include an oxime group in their structure. AL-516, AL-522B, CG-92, CG-105, CG-147, CG-151 and 
CG-153 consist in structures with a hydrazone group. 
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CG-147 was the simplest model of a hydrazone derivative. CG-151 and CG-153 
had different R2 group whereby CG-153 (R2=OH) presented higher biological activity in 
EL-4 and THP-1. Comparing CG-153 with CG-147, the biological activity in EL-4 and THP-
1 was similar and CG-147 was more active in U937.  
 The R1 activity influenced by CG-92 and CG-105 was cell dependent. CG-92 was 
more active in THP-1 and CG-105 was in EL-4. Comparing CG-147 with CG-92 and CG-
105, it was possible to affirm that in EL-4, R1=CH2-phenil was more active biologically 
and in THP-1 and U937, R1=CH3 was a better choice.  
 AL-516 and AL-522B differed in R3. This difference allowed to conclude that AL-
516 was more active in all the cancer cells, however, not selective (as explained below). 
Between AL-516 and CG-147, AL-516 showed lower IC50.   
Comparing 9a, the oxime with the best biological activity, with AL-516, the 
hydrazone with better results, 9a had better biological activity results: 1,65 µM versus 
5,45 µM (EL-4), 1,62 µM versus 14,00 µM (THP-1) and 1,64 µM versus 13,3 µM (U937).  
Other comparative analysis consisted in 9a and etoposide (positive control), 
which presented similar IC50 values and, consequently, similar cytotoxic activity.  
 
Based in the cytotoxic assay best-fit value, the selectivity of compounds was 
calculated. This value was obtained by the ratio between IC50 of the compounds towards 
S17 cell line and the IC50 of the same compound towards each tumoural cell line. 
 
 
𝑆𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝐼𝐶50(𝑆17, 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑥)
𝐼𝐶50(𝑡𝑢𝑚𝑜𝑢𝑟𝑎𝑙 𝑐𝑒𝑙𝑙 𝑙𝑖𝑛𝑒, 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑥)
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Table  III-2. Selectivity results. This table shows the selective value of studied compounds for the different tested cell 
lines (EL-4, THP-1 and U937), comparatively to S17. Green numbers signalize the higher selectivity values. 
Selectivity 
Compounds / 
Cell lines 
EL-4 THP-1 U937 
Etoposide 3,60 9,70 16,05 
AL-516 1,45 0,57 0,59 
AL-522B 3,10 2,49 2,55 
CG-105 1,37 0,20 --- 
CG-109 1,91 0,79 0,98 
CG-141 3,57 1,82 1,18 
CG-142 1,40 1,41 1,71 
CG-147 2,97 1,52 1,82 
CG-151 1,83 1,14 1,46 
CG-153 2,59 1,40 0,25 
 
 
 Comparing the selectivity values of BIM derivatives, compounds AL-522B and CG-
141 were the most selective between tumoural and non-tumoural cells.  AL-522B was 
the most selective compound, considering the three cell lines, with higher value in EL-4.  
Compound 9a remains the most selective towards S17, presenting  selectivity 
values of the same order to the three different cell lines: 9,86 (EL-4), 10,04 (THP-1) and 
9,92 (U937) (71).  
When compared with etoposide, compound 9a was more selective in U937 but 
less in EL-4.   
 
 
3.1.2 Hemolytic activity 
  
 Hemolysis consists on the damage to red blood cells, releasing hemoglobin that 
can be measured determining the hemolysis percentage.   
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 The assay studied compounds as well as DMSO (solvent of compounds – negative 
control), milli-Q water (positive control) and PBS (negative control).  
CG-141 was the compound with higher hemolysis percentage (14,8%). All the 
other compounds presented very low hemolytic activities; between 3,9% and 5,2%. 
The hemolytic assay allowed concluding that the study compounds do not have 
significant activity against red blood cells. These results corroborate some data referred 
in the introduction, which mention BIM activity in nuclear mechanisms. Red blood cells 
are anucleated cells which justify the lack of activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table  III-3. Hemolytic activity results of tested compounds, expressed as mean ± SEM, 95% Confidence. 
 
 
Positive 
control 
Negative 
control 
DMSO 
AL-
516, 
100µM 
AL-
522B, 
100µM 
CG-
105, 
100µM 
CG-
109, 
100µM 
CG-
141, 
100µM 
CG-
142, 
100µM 
CG-
147, 
100µM 
CG-
151, 
100µM 
CG-
153, 
100µM 
Mean 100 3,90 4,2 4,48 4,55 3,78 5,19 14,8 4,88 3,93 3,88 4,02 
SEM 1,98 0,17 0,39 0,54 0,82 0,06 7,41 10,7 0,29 0,10 0,07 0,17 
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Graphic III-3. Hemolysis percentage graph of tested compounds. Results are expressed 
as mean ± SEM, 95% Confidence. 
 
 
Graphic III-4. Hemolysis percentage graph of tested compounds. Results are expressed 
as mean ± SEM, 95% Confidence. 
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3.2 BIMs versus actual therapeutics  
 
The third proposed objective was the structural comparison of the studied 
compounds with drugs that are currently being used to treat cancer. Comparing BIMs 
with the anticancer drugs presented in section 1.1.3, the two indoles present in BIMs 
(pharmacophore) are also present in the structures of vinca alkaloids (Fig. III-1). Vinca 
alkaloids present anticancer activity through mitosis inhibition due to tubulin 
polymerization, and such activity is attributed to the presence of the indole structures. 
It is thus possible that the compounds studied in this work act upon cancer cells through 
a similar mechanism of action. Further studies are, however, needed to confirm this 
hypothesis. 
 
 
Figure III-1. Comparison between BIM and actual therapeutic chemical structures.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
                  
                            Vinorelbine  
 
 
DIM 
 
BIM 
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3.3 Experimental Limitations  
 
 During the experimental component, there were some difficulties, which are 
important to refer:  
- the use of cell lines coming from different organisms can justify the different 
response to the tested compounds (EL-4 and S17 are murine cells while THP-1 
and U937 where human); 
- the use of suspension cell lines (EL-4, THP-1 and U937) and adherent cell lines 
(S17) could have influenced the cellular response to the compounds and hence 
affect the evaluation of the testes compounds selectivity;  
- the use of small volumes during the cell culture and during the compounds 
preparation could have resulted in measurement errors; 
- the existence of suspended cells and non-suspended cells contributed to 
additional steps during the assays and consequently loss of cells, affecting the 
final result; 
- in the hemolysis assay, the blood viscosity conditioned the drop’s volume used 
in the assay as well as the removal of the supernatant.  
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IV. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The existence of side effects, development of resistance by tumour cells and the 
necessity of more specific anticancer mechanisms are the main reasons to investigate 
new drugs able to improve the efficacy and reduce the toxicity of therapeutics. Actually, 
BIMs have described biological activities such as antibacterial, antifungal, analgesic, anti-
inflammatory, anthelmintic, cardiovascular and anticancer activity (52).  
In the course of this work, the main objectives were to study the cytotoxic activity 
of BIMs derivatives, to relate their chemical structure with the cytotoxic activity and to 
compare BIMs with actual therapeutics. The results revealed that CG-141 was the most 
active compounds towards EL-4 (IC50=3,01-3,47 µM), THP-1 (IC50=5,79-6,94 µM) and 
U937 (IC50=9,79-10,3 µM) while AL-522B was the most selective compound towards S17 
(EL-4: 3,10; THP-1: 2,49; U937:2,55). When compared with hydrazone derivatives, oxime 
derivatives had a stronger biological activity in the studied cell lines.  
As result of the comparison between the studied compounds with the compound 
9a, it was possible to conclude that 9a continues to be the most biological active 
compound towards EL-4 (IC50=1.65±0.02µM), THP-1 (IC50=1.62±0.08µM) and U937 
(IC50=1.64±0.08µM) and the most selective towards S17 (9,86; 10,04; and 9,92, 
respectively).  This comparison allowed to conclude that a hydrogen in the R2 BIM 
position increased the biological activity results.  
The similar IC50 between the etoposide and 9a compound suggest that 9a has 
potential to be a therapeutic drug, due to the cytotoxic activity demonstrated.  BIMs 
and vinca alkaloids have the same pharmacophores, which suggest possible 
resemblance to the action mechanism, namely in tubulin polymerization.  
None of the studied compounds presented significant hemolytic activity in 
hemolytic assay, which corroborated the theory of a nuclear action mechanism. 
 
 As future perspectives, new structural approaches and biological studies can be 
considered. Structurally speaking, the studies undertaken shown that BIMs bearing 
oxime and hydrazone moieties with alkyl and aryl substituents in R3 BIM position may 
be promising compound for treatment of non-adherent tumour cells. Further studies of 
BIMs involving heteroaryl, phosphoryl, carbonyl and carboxyl motifs at the oxime and/or 
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hydrazone moiety would be very interesting, since these groups are also present in 
anticancer drugs used in therapeutic.  
 The biological cytotoxicity determination in human suspension cell lines of the 
compounds, instead of EL-4 and S17 (both murine cell lines), constitutes a possible 
future assay, since it allows comparisons between tumoural and non-tumoural 
suspension cell lines of the same organism. Furthermore, the evaluation of proteins such 
as tubulin, which regulates cellular cycle, and the determination of the antioxidant 
activity of BIMs, constitute possible assays that could be useful to complement the data 
presented, explaining BIM anticancer mechanisms.  
  To conclude, additional strategies of chemical structure and biological assays 
should be done to complement the data presented here and to improve new molecules 
with anticancer activity potential.  
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VI. ANNEXES 
 
7.1 Chemical Structures of compounds 
 
The compounds are illustrated by alphabetic order.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AL-516 chemical structure. 
 
 
Figure VI-1. AL-522B chemical structure.Figure 
VI-2. AL-516 chemical structure. 
 
 
Figure VI-3. AL-516 chemical structure. 
 
 
Figure VI-4. AL-522B chemical structure.Figure 
VI-5. AL-516 chemical structure. 
 
 
AL-516 chemical structure. 
 
 
Figure VI-6. AL-522B chemical structure.Figure 
VI-7. AL-516 chemical structure. 
 
 
Figure VI-8. AL-516 chemical structure. 
 
 
AL-522B chemical structure. 
 
 
Figure VI-11. CG-92 chemical 
structure.Figure VI-12. AL-522B chemical 
structure. 
 
 
Figure VI-13. AL-522B chemical structure. 
 
 
Figure VI-14. CG-92 chemical 
structure.Figure VI-15. AL-522B chemical 
structure. 
 
 
AL-522B chemical structure. 
 
 
Figure VI-16. CG-92 chemical 
structure.Figure VI-17. AL-522B chemical 
structure. 
 
 
Figure VI-18. AL-522B chemical structure. 
 
CG-92 chemical structure. 
 
Figure VI-21. CG-92 chemical structure. 
 
CG-92 chemical structure. 
 
Figure VI-22. CG-92 chemical structure. 
CG-99.1 chemical structure. 
CG-105 chemical structure. 
 
Figure VI-23. CG-105 chemical structure.  
 
CG-109 chemical structure. 
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CG-141 chemical structure. 
 
Figure VI-29. CG-141 chemical structure. 
 
Figure VI-30. CG-141 chemical structure. 
 
Figure VI-31. CG-141 chemical structure. 
 
CG-141 chemical structure. 
 
Figure VI-32. CG-141 chemical structure. 
 
Figure VI-33. CG-141 chemical structure. 
 
Figure VI-34. CG-141 chemical structure. 
CG-142 chemical structure. 
 
CG-142 chemical structure. 
 CG-147 chemical structure. 
 
Figure VI-35. CG-151 chemical 
structure.Figure VI-36. CG-147 chemical 
structure. 
 
Figure VI-37. CG-147 chemical structure. 
 
Figure VI-38. CG-151 chemical 
structure.Figure VI-39. CG-147 chemical 
structure. 
 
 CG-147 chemical structure. 
 
Figure VI-40. CG-151 chemical 
structure.Figure VI-41. CG-147 chemical 
structure. 
 
Figure VI-42. CG-147 chemical structure. 
 
Figure VI-43. CG-151 chemical 
structure.Figure VI-44. CG-147 chemical 
structure. 
CG-151 chemical structure. 
 
Figure VI-45. CG-151 chemical structure. 
 
Figure VI-46. CG-151 chemical structure. 
 
Figure VI-47. CG-151 chemical structure. 
 
CG-151 chemical structure. 
 
Figure VI-48. CG-151 chemical structure. 
 
Figure VI-49. CG-151 chemical structure. 
 
Figure VI-50. CG-151 chemical structure. 
CG-153 chemical structure. 
 
Graph VI-1. AL-516 IC50 curve in EL-4, 
based on MTT colourimetric assay. EL-4 
were tested with AL-516 at 100, 50, 25, 
12.5, 10, 5, 2.5 and 1µM, prepared in 
DMSO solution. The half-maximal 
inhibitory concentration (IC50) of AL-16 in 
EL-4 cell line has a 95% confidence interval 
of 5,20 to 5,73µM.Figure VI-51. CG-153 
chemical structure.  
 
Graph VI-2. AL-516 IC50 curve in EL-4, 
based on MTT colourimetric assay. EL-4 
were tested with AL-516 at 100, 50, 25, 
12.5, 10, 5, 2.5 and 1µM, prepared in 
DMSO solution. The half-maximal 
inhibitory concentration (IC50) of AL-16 in 
EL-4 cell line has a 95% confidence interval 
of 5,20 to 5,73µM.Figure VI-52. CG-153 
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7.2 IC50 curves 
 
 
IC50 curves with AL-516 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AL-516 IC50 curve in THP-1, based on MTT colourimetric assay. THP-1 
was tested with AL-516 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of AL-516 in THP-1 cell line has a 95% confidence interval of 12,2 to 
16,1 µM.  
AL-516 IC50 curve in EL-4, based on MTT colourimetric assay. EL-4 was 
tested with AL-516 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of AL-516 
in EL-4 cell line has a 95% confidence interval of 5,20 to 5,73 µM. 
IC50: 5,20 to 5,73 µM 
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IC50: 12,2 to 16,1 µM 
 
IC50: 12,2 to 16,1 µM 
 
IC50: 12,2 to 16,1 µM 
 
IC50: 12,2 to 16,1 µM 
 
IC50: 12,2 to 16,1 µM 
 
IC50: 12,2 to 16,1 µM 
 
IC50: 12,2 to 16,1 µM 
 
IC50: 12,2 to 16,1 µM 
AL-516 IC50 curve in U937, based on MTT colourimetric assay. U937 
was tested with AL-516 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of AL-516 in U937 cell line has a 95% confidence interval of 12,0 to 14,8 
µM. 
IC50: 12,0 to 14,8 µM IC50: 6,88 to 9,11 µM 
AL-516 IC50 curve in S17, based on MTT colourimetric assay. S17 was 
tested with AL-516 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of AL-516 
in S17 cell line has a 95% confidence interval of 6,88 to 9,11 µM. 
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IC50 curves with AL-522B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IC50: 16,4 to 21,7 µM 
AL-522B IC50 curve in EL-4, based on MTT colourimetric assay. EL-4 was 
tested with AL-522B at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of AL-
522B in EL-4 cell line has a 95% confidence interval of 16,4 to 21,7 µM. 
AL-522B IC50 curve in THP-1, based on MTT colourimetric assay. THP-1 
was tested with AL-522B at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of AL-522B in THP-1 cell line has a 95% confidence interval of 20,2 to 
27,2 µM. 
IC50: 20,2 to 27,2 µM 
AL-522B IC50 curve in U937, based on MTT colourimetric assay. U937 
was tested with AL-522B at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of AL-522B in U937 cell line has a 95% confidence interval of 20,3 to 
25,9 µM. 
IC50: 20,3 to 25,9 µM IC50: 48,9 to 70,0 µM 
AL-522B IC50 curve in S17, based on MTT colourimetric assay. S17 was 
tested with AL-522B at 100, 80, 60, 50, 40, 30, 20 and 15 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of AL-
522B in S17 cell line has a 95% confidence interval of 20,3 to 25,9 µM. 
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IC50 curves with CG-105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
CG-105 IC50 curve in EL-4, based on MTT colourimetric assay. EL-4 was 
tested with CG-105 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of CG-105 
in EL-4 cell line has a 95% confidence interval of 5,12 to 6,05 µM. 
IC50: 5,12 to 6,05 µM 
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CG-105 IC50 curve in THP-1, based on MTT colourimetric assay. THP-1 
was tested with CG-105 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-105 in THP-1 cell line has a 95% confidence interval of 31,3 to 48,2 
µM. 
IC50: 31,3 to 48,2 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
CG-105 IC50 curve in S17, based on MTT colourimetric assay. S17 was 
tested with CG-105 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of CG-105 
in S17 cell line has a 95% confidence interval of 3,95 to 14,8 µM. 
IC50: 3,95 to 14,8 µM 
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IC50 curves with CG-109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
IC50: 8,77 to 9,85 µM 
CG-109 IC50 curve in EL-4, based on MTT colourimetric assay. EL-4 was 
tested with CG-109 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of CG-109 
in EL-4 cell line has a 95% confidence interval of 8,77 to 9,85 µM. 
CG-109 IC50 curve in THP-1, based on MTT colourimetric assay. THP-1 
was tested with CG-109 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-109 in THP-1 cell line has a 95% confidence interval of 21,0 to 24,3 
µM. 
IC50: 21,0 to 24,3 µM 
IC50: 16,2 to 20,1 µM 
CG-109 IC50 curve in U937, based on MTT colourimetric assay. U937 
was tested with CG-109 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-109 in U937 cell line has a 95% confidence interval of 16,2 to 20,1 
µM. 
IC50: 14,9 to 21,1 µM 
CG-109 IC50 curve in S17, based on MTT colourimetric assay. S17 was 
tested with CG-109 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of CG-109 
in S17 cell line has a 95% confidence interval of 14,9 to 21,1 µM. 
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IC50 curves with CG-141 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
IC50: 3,01 to 3,47 µM 
CG-141 IC50 curve in EL-4, based on MTT colourimetric assay. EL-4 was 
tested with CG-141 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of CG-141 
in EL-4 cell line has a 95% confidence interval of 3,01 to 3,47 µM. 
IC50: 5,79 to 6,94 µM 
CG-141 IC50 curve in THP-1, based on MTT colourimetric assay. THP-1 
was tested with CG-141 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-141 in EL-4 cell line has a 95% confidence interval of 5,79 to 6,94 
µM. 
IC50: 9,36 to 10,3 µM 
CG-141 IC50 curve in U937, based on MTT colourimetric assay. U937 
was tested with CG-141 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-141 in U937 cell line has a 95% confidence interval of 9,36 to 10,3 
µM. 
IC50: 11,2 to 11,9 µM 
CG-141 IC50 curve in S17, based on MTT colourimetric assay. S17 was 
tested with CG-141 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of CG-141 
in S17 cell line has a 95% confidence interval of 11,2 to 11,9 µM. 
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IC50 curves with CG-142 
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IC50: 13,7 to 17,9 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
CG-142 IC50 curve in EL-4, based on MTT colourimetric assay. EL-4 was 
tested with CG-142 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of CG-142 
in EL-4 cell line has a 95% confidence interval of 13,7 to 17,9 µM. 
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IC50: 14,2 to 16,9 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
CG-142 IC50 curve in THP-1, based on MTT colourimetric assay. THP-1 
was tested with CG-142 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-142 in THP-1 cell line has a 95% confidence interval of 14,2 to 16,9 
µM. 
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CG-142 IC50 curve in U937, based on MTT colourimetric assay. U937 
was tested with CG-142 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-142 in U937 cell line has a 95% confidence interval of 12,0 to 13,7 
µM. 
IC50: 12,0 to 13,7 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
 
IC50: 5,20 to 5,73 µM 
CG-142 IC50 curve in S17, based on MTT colourimetric assay. S17 was 
tested with CG-142 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of CG-142 
in S17 cell line has a 95% confidence interval of 16,7 to 28,7 µM. 
IC50: 16,7 to 28,7 µM 
Evaluation of Cytotoxic Activity of Synthetic Bis-Indolyl Methanes:  
Structure-Activity Relationship 
 
 
65 
 
 
IC50 curves with CG-147 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
  
 
 
IC50: 13,7 to 17,1 µM 
CG-147 IC50 curve in EL-4, based on MTT colourimetric assay. EL-4 was 
tested with CG-147 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of CG-147 
in EL-4 cell line has a 95% confidence interval of 13,7 to 17,1 µM. 
IC50: 24,9 to 35,8 µM 
CG-147 IC50 curve in THP-1, based on MTT colourimetric assay. THP-1 
was tested with CG-147 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-147 in THP-1 cell line has a 95% confidence interval of 24,9 to 35,8 
µM. 
CG-147 IC50 curve in U937, based on MTT colourimetric assay. U937 
was tested with CG-147 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-147 in U937 cell line has a 95% confidence interval of 26,7 to 26,4 
µM. 
IC50: 26,7 to 26,4 µM 
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IC50: 42,6 to 48,6 µM 
 
IC50: 5,20 to 5,73 µM 
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CG-147 IC50 curve in S17, based on MTT colourimetric assay. S17 was 
tested with CG-147 at 200, 150, 100, 75, 50, 25 and 10 µM, prepared in 
DMSO solution. The half-maximal inhibitory concentration of CG-147 in 
S17 cell line has a 95% confidence interval of 42,6 to 48,6 µM. 
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IC50 curves with CG-151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
IC50: 19,6 to 25,9 µM 
CG-151 IC50 curve in EL-4, based on MTT colourimetric assay. EL-4 was 
tested with CG-151 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of CG-151 
in EL-4 cell line has a 95% confidence interval of 19,6 to 25,9 µM. 
IC50: 32,5 to 40,4 µM 
CG-151 IC50 curve in THP-1, based on MTT colourimetric assay. THP-1 
was tested with CG-151 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-151 in THP-1 cell line has a 95% confidence interval of 32,5 to 40,4 
µM. 
CG-151 IC50 curve in U937, based on MTT colourimetric assay. U937 
was tested with CG-151 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-151 in U937 cell line has a 95% confidence interval of 21,3 to 37,9 
µM. 
IC50: 21,3 to 37,9 µM 
IC50: 36,9 to 46,2 µM 
CG-151 IC50 curve in S17, based on MTT colourimetric assay. S17 was 
tested with CG-151 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of CG-151 
in S17 cell line has a 95% confidence interval of 36,9 to 46,2 µM. 
Evaluation of Cytotoxic Activity of Synthetic Bis-Indolyl Methanes:  
Structure-Activity Relationship 
 
 
67 
 
 
IC50 curves with CG-153 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
CG-153 IC50 curve in EL-4, based on MTT colourimetric assay. EL-4 was 
tested with CG-153 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, prepared 
in DMSO solution. The half-maximal inhibitory concentration of CG-153 
in EL-4 cell line has a 95% confidence interval of 12,9 to 18,4 µM. 
IC50: 12,9 to 18,4 µM 
IC50: 24,4 to 33,5 µM 
CG-153 IC50 curve in THP-1, based on MTT colourimetric assay. THP-1 
was tested with CG-153 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-153 in THP-1 cell line has a 95% confidence interval of 24,4 to 33,5 
µM. 
IC50: 4,83 to 5105 µM 
CG-153 IC50 curve in U937, based on MTT colourimetric assay. U937 
was tested with CG-153 at 100, 50, 25, 12.5, 10, 5, 2.5 and 1 µM, 
prepared in DMSO solution. The half-maximal inhibitory concentration 
of CG-153 in U937 cell line has a 95% confidence interval of 4,83 to 5105 
µM. 
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IC50: 33,4 to 47,6 µM 
 
IC50: 5,20 to 5,73 µM 
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IC50: 5,20 to 5,73 µM 
CG-153 IC50 curve in S17, based on MTT colourimetric assay. S17 was 
tested with CG-153 at 200, 150, 100, 75, 50, 25 and 10 µM, prepared in 
DMSO solution. The half-maximal inhibitory concentration of CG-153 in 
S17 cell line has a 95% confidence interval of 33,4 to 47,6 µM. 
